Kornimate/medical-research-clean huggingface dataset:
early support in primary care for people starting treatment for cancer

Conditions: Cancer of Pancreas; Cancer of Stomach; Cancer of Esophagus

Summary: this is a feasibility, randomised controlled trial (rct) of a person-centred care planning intervention involving patients recently diagnosed with a poor prognosis cancer who are starting a palliative oncology treatment in a scottish regional cancer centre.

this study will evaluate the feasibility and acceptability of an early 'palliative care' intervention consisting of anticipatory care planning coordinated in primary care that is systematically triggered when patients with poor prognosis gastrointestinal cancers start palliative oncology treatment. patients will be identified and invited to participate during their assessment and treatment planning by the cancer care clinicians. a screening log will record eligible cases. patients who consent will be randomised to receive a letter about the benefits of early anticipatory care planning to take to their preferred general practitioner to help trigger earlier support by their primary care team. control patients receive usual care. all study patients will be asked to complete 3 questionnaires (euroqol eq-5d-5l (full title of tool), icecap supportive care measure (full title of tool), and collaborate (full title of tool) for shared decision-making) at baseline, 6, 12, 24 and 48 weeks. a purposive sub-sample of patients, family carer and general practitioner (gp) triads will be invited for interview at around 6 and 20 weeks to explore their experiences of trial participation, their illness and care. health service use will be recorded including hospital admissions, oncology treatment, palliative care referral, time and place of death or survivorship.

Eligibility criteria:
inclusion criteria: * people with advanced, inoperable oesophageal, gastric or pancreatic cancers * people being offered palliative chemotherapy and/or radiotherapy exclusion criteria: * people too ill to participate or give informed consent. * patient who are not fit for oncology treatment or who opt for best supportive care. * people with other life-limiting conditions likely to cause death within 6 months. * people with moderate to severe cognitive impairment that precludes completions of questionnaires or participation in interviews. * people unable to give informed consent or communicate by telephone with the researcher.

Keywords: oncology palliative care primary care care planning
seinäjoki adult asthma study

Conditions: Asthma

Summary: seinäjoki adult asthma study is a single-centre 12-year follow-up study of a total cohort of 259 patients having new-onset asthma that was diagnosed at adult age. the study was divided in two parts: the collection of the original cohort (phase i;n=259) and follow-up visit (phase ii; n=203). the aim of this study is to increase the understanding on the diagnostics and diagnostic process, organisation of the long-term asthma care, therapeutic outcomes, prognosis and the factors affecting the prognosis of new-onset asthma diagnosed at adult age.

at baseline visit the diagnostic studies performed were: spirometry, pef (peak expiratory flow) follow-up, other respiratory physiology measurements, laboratory, skin-prick, aq20 (airways questionnaire 20), 15d, background data. at follow-up visit, asthma status, co-morbidities (chronic rhinitis or obstructed nose, allergic rhinitis or conjunctivitis, diabetes, hypertension, coronary heart disease, copd (chronic obstructive pulmonary disease) and any other patient-reported disease), medication (including medication to other diseases and the disease treated), control, severity and lung function were evaluated. in addition to the data gathered at these visits, data on asthma follow-up visits, exacerbations, hospitalisations, possible occupationally induced asthma and prescribed asthma medication were collected from hospital clinics, primary health care, occupational health care and private practices for the whole 12-year follow-up period. in addition, the use of medication that was realised, i.e., medication bought from pharmacy, will be retrieved. in addition to asthma-specific factors, data include occupational, lifestyle and socioeconomic factors at the follow-up visit.

Eligibility criteria:
inclusion criteria: * a diagnosis of new-onset asthma made by a respiratory specialist * diagnosis confirmed by at least one of the following objective lung function measurements * fev1 (forced expiratory volume in one second) reversibility in spirometry of at least 15% and 200 ml * diurnal variability (⩾20%) or repeated reversibility (⩾15%/60 l/min) in pef follow-up * a significant decrease in fev1 (15%) or pef (20%) in response to exercise or allergen * a significant reversibility in fev1 (at least 15% and 200 ml) or significant mean pef in response to a trial with oral or inhaled glucocorticoids * symptoms of asthma * age ≥15 years exclusion criteria: * physical or mental inability to provide signed informed consent * diagnosis of asthma below the age of 15 years
inflammation and coagulation factors for predicting cerebral edema after sah

Conditions: Inflammation; Coagulation and Hemorrhagic Disorders; Cerebral Edema

Summary: explore the role of inflammation and coagulation factors in cerebrospinal fluid for predicting persistent cerebral edema after subarachnoid hemorrhage


Eligibility criteria:
inclusion criteria: * subarachnoid hemorrhage patients admitted to our neurosurgery department with modified fisher scale 3-4, with a confirmed radiographic diagnosis. exclusion criteria: * angiogram-negative patients, patients with a history of trauma or previous brain injury (stroke, hemorrhage, surgery et al. which left associated chronic changes on ct), arteriovenous malformation, radiological data lost, accompany with serious comorbidities before subarachnoid hemorrhage onset (such as coagulation defects, uncontrollable hypertension, and arrhythmia et.al.), initial radiological data performed more than 3 days after sah onset
vaccination with tumor mrna in metastatic melanoma - fixed combination versus individual selection of targeted antigens

Conditions: Malignant Melanoma

Summary: the purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mrna coding for the corresponding antigen.

vaccination protocol to induce clinically specific immune responses against melanoma associated antigens by intradermal injections of mrna coding for the corresponding antigens. half of patients is treated with mrna coding for melan-a, mage-a1, mage-a3, survivin, gp100 and tyrosinase. the other half of patients is treated with an individualized selection of mrnas after analysis of overexpressed melanoma antigens in autologous tumor tissue. gm-csf is used as an adjuvants. phase i/ii clinical trial to analyse safety and immune responses in stage iii/iv melanoma patients.

Eligibility criteria:
inclusion criteria: * malignant melanoma stage iii/iv * fresh frozen tumor tissue available * informed consent given * karnofsky \>= 70% exclusion criteria: * brain metastasis * parallel chemotherapy * systemic treatment with glucocorticoids * other malignancies

Keywords: vaccination mrna
thalidomide and rituximab in waldenstrom's macroglobulinemia

Conditions: Waldenstrom's Macroglobulinemia; Lymphoplasmacytic Lymphoma

Summary: the purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.

* patients will receive thalidomide(200mg) orally once daily for two weeks. if after two weeks of thalidomide, the patient is doing well the dose of thalidomide will increase (400mg) and they will remain on it for up to 50 additional weeks. the length of time a patient is on thalidomide will depend upon how they are responding to therapy. * during the second week of the study patients will also begin receiving rituximab intravenously once weekly for 4 weeks, which may then be repeated 8 weeks later depending upon the response. * a determination of how the patient is responding will be made based on testing conducted at 12 weeks. this testing includes blood tests and possibly a bone marrow biopsy. if it is determined that the disease is not progressing, patients will begin a second phase of treatment which includes 4 additional weekly infusions of rituximab and the continuation of oral thalidomide. * if it is determined at the 12-week evaluation, or at any time thereafter, that the disease has progressed (by studying serum immunoglobulin m (igm) levels, bone marrow involvement, tumor cells, and/or development of new signs and symptoms) then the patient will be removed from the study. * periodic examinations and tests will be done to determine how the patient is doing, what response and side effects (if any) the patient may be having from the study drugs. if patient is responding to therapy then they will remain on this study and followed for a period of two years. * bone marrow biopsies and aspirations will be obtained at 3-6 month intervals extending for 2 years following the last treatment.

Eligibility criteria:
inclusion criteria: * clinicopathological diagnosis of waldenstrom's macroglobulinemia requiring therapy * baseline staging requirements * absolute neutrophil count \> 500/microliter (ul) * platelet count \> 25,000/ul * serum creatinine \< 2.5mg/dl * total bilirubin and transaminase (sgot) \< 2.5 x upper limit of normal (uln) * greater than 18 years of age * life expectancy of 3 months or greater * eastern cooperative oncology group (ecog) status performance of 0-2 exclusion criteria: * chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry * pregnant or lactating women * serious co-morbid disease * uncontrolled bacterial, fungal or viral infection * active second malignancy

Keywords: thalidomide rituximab waldenstrom's
wellness intervention for menstrual mood disorders

Conditions: Menstrual Mood Disorders

Summary: this study has been funded by national institute of mental health (nimh) to compare two behavioral interventions for menstrual mood disorders, including premenstrual dysphoric disorder (pmdd). both of these interventions will be run in a group format, meaning that you will be part of a group of other women who have a menstrual mood disorder. both of these interventions will be run by experienced mental health professionals and both interventions have been shown to be effective in reducing mood symptoms, increasing a sense of well-being, and helping individuals cope with stress. while it is expected that both interventions to be associated with some benefit, this study is designed to see which is better for women with a menstrual mood disorder.


Eligibility criteria:
inclusion criteria: * meets prospective criteria for a menstrual mood disorder, including pmdd * depression symptom severity and functional impairment based on prospective symptom ratings for 2-3 cycles using the daily record of severity of problems (drsp) * clear remission of all symptoms during days 6-10 * 18 - 55 years of age * regular menstrual cycles * early life sexual or physical abuse (50% of sample) or no history of sexual or physical abuse (50% of sample) * absence of current ptsd symptoms using the 17-item ptsd checklist (pcl) * 8th grade literacy level * ability to give informed consent exclusion criteria: * current axis i disorder or suicide ideation (histories of depression, anxiety, substance abuse, and eating disorders are allowed if in remission for \>2 years) * premenstrual exacerbation of chronic disorders * in a current abusive relationship or residing with a former abuser * a lifetime history of suicide attempt, or suicidal thoughts or gestures within 5 years of study enrollment * histories of bipolar or psychotic disorders * age \ 55 years * pregnancy or breastfeeding * use of psychotropic, hormonal or other agents that alter mood or biological mediators * current functional pain disorder * a history of meditation practice (2+ times/week for 15+ min; some yoga allowed) * diabetes * bmi \< 18.5 * vigorous exercise * stage 2 hypertension * any symptom item rated \>2 (moderate or higher) or a total score \> 24 on the ptsd checklist
hetrombopag in promoting platelet engraftment after auto-hsct in children with neuroblastoma

Conditions: Delayed Platelet Engraftment; Neuroblastoma; Autologous Hematopoietic Stem Cell Transplantation

Summary: the goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. the main question it aims to answer is: · does drug hetrombopag promote platelet engraftment? participants will take hetrombopag every day for 6 weeks or until platelet \&gt; 100\*10\^9/l.


Eligibility criteria:
inclusion criteria: * age\<18 years old; * diagnosed as neuroblastoma; * ecog ≤ 2; * first time receiving autologous hematopoietic stem cell transplantation; * the subjects or their legal guardians agree to participate and sign the informed consent form. exclusion criteria: * alt/ast \> 3 uln, or tbil \> 1.5 uln; * have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment; * suffering from thromboembolic diseases; * other situations that are not suitable for inclusion in the study determined by researchers.

Keywords: hetrombopag delayed platelet engraftment neuroblastoma pediatrics autologous hematopoietic stem cell transplantation
leptin receptors in the bariatric surgical population within the university of pittsburgh medical system: a cohort study

Conditions: Obesity

Summary: prospective cohort study evaluating the role of leptin receptors in the bariatric surgical population compared with non obese controls. additionally serum levels of leptin, ghrelin, motilin and pyy will be compared amongst the different bmi classes and a quality of life questionnaire completed by all participants. the hypothesis is that obese individuals have lower leptin receptors in enterocytes which is partially responsible for the higher serum leptin levels without appropriate control of satiety.


Eligibility criteria:
inclusion criteria: * endoscopic intervention exclusion criteria: * 18 years of age or older * no acute gi bleeding

Keywords: obesity leptin
optimization of spleen vcte examinations with fibroscan

Conditions: Spleen; Fibrosis

Summary: this is an european, prospective, interventional, and multicenter clinical investigation which main objective is to develop a spleen examination dedicated to overweight or obese patients and assess its applicability. it will take place in 4 sites (1 site in the netherlands, 2 sites in spain and 1 site in romania) to include a total of 500 patients (adults and children).


Eligibility criteria:
inclusion criteria: 1. adult or pediatric patient able to give written informed consent (parents/legal tutors in case of minor patients), 2. patient affiliated to the healthcare system 3. adult or children patient followed for a liver disease a suspicion of liver disease or for a consequence of a liver disease, with or without splenomegaly and having a spleen to skin distance (ssd) measurement performed during the screening ultrasound exam. exclusion criteria: 1. vulnerable patient- other than pediatric patients 2. patients with ascites

Keywords: fibroscan vibration control transient elastography spleen stiffness measurement
adt exercise trial and economic analysis

Conditions: Prostate Cancer

Summary: prostate cancer (pc) affects 1 in 7 men. nearly half of those diagnosed with pc will receive androgen deprivation therapy (adt) as part of their treatment. adt is good at managing pc but has many side effects. researchers have shown that exercise, specifically one-on-one supervised exercise improves many of the side effects of adt. however, exercise programs for men on adt are not widely available. more questions need to be answered in order for exercise programs to become part of pc treatment. first, can programs that require fewer resources, such as group-exercise or home-based exercise, also improve adt side-effects? second, do exercise-related benefits continue beyond the structured exercise program? and what makes people continue exercising? third, which exercise program is most cost-effective? in this study, the investigators will compare: (a) group supervised in-centre and (b) home-based supported exercise programs to see which program is most effective for men with pc on adt. the investigators will also look at what motivates people to continue to exercise both during a structured program and after the program is complete and will examine which exercise program is most cost-effective. participants (men with pc on adt) will be recruited from one of the following cancer centres: princess margaret cancer centre in toronto, the tom baker cancer centre in calgary, the southlake regional health centre in newmarket, and scarborough and rouge hospital - centenary site in scarborough. when a patient agrees to participate, patient will be randomly placed in 1 of 2 exercise programs. all programs will include the same type of exercises (aerobic, resistance and flexibility) and all participants will exercise 4-5 days per week for 30 minutes per day (as tolerated) for the length of the program (6 months). the investigators will look at how men with pc on adt respond to the exercise program by measuring quality of life (qol), fatigue and different physical measures before, during, and after the exercise program. although the investigators know that supervised one-on-one exercise is most effective at improving adt side-effects, it is unknown if other forms of exercise are just as beneficial and more financially responsible. this study will allow the investigators to begin to answer these questions so that structured exercise programs become a regular part of pc treatment.


Eligibility criteria:
inclusion criteria: * men with histologically confirmed pc who are starting or continuing on adt for at least 6 months or who are in an androgen-deprived (or castrate) state for the duration of the intervention * fluent in english * able to provide consent * close to a study centre exclusion criteria: * already meeting guidelines for moderate to vigorous physical activity (mvpa) - conditions that would interfere with ability to participate
squalamine lactate eye drops in combination with ranibizumab in patients with diabetic macular edema (dme)

Conditions: Diabetic Retinopathy

Summary: a randomized, controlled study of the safety and efficacy of squalamine lactate eye drops in combination with ranibizumab intravitreal injections in patients with diabetic macular edema. the study duration is 52 weeks and patients will be randomized to one of four treatment arms.

a randomized, controlled study of the safety and efficacy of squalamine lactate eye drops in combination with ranibizumab intravitreal injections in patients with diabetic macular edema. subjects will be randomized to one of the following treatment arms: 1. squalamine lactate ophthalmic solution administered twice a day for 52 weeks in combination with monthly injections of ranibizumab from baseline through week 20 and ranibizumab as needed from week 24 through week 52. 2. vehicle ophthalmic solution administered twice a day for 52 weeks in combination with monthly injection of ranibizumab from baseline through week 20 and ranibizumab as needed from week 24 through week 52. 3. squalamine lactate ophthalmic solution administered four times a day for 52 weeks in combination with monthly injections of ranibizumab from baseline through week 20 and ranibizumab as needed from week 24 through week 52. 4. vehicle ophthalmic solution administered four times a day for 52 weeks in combination with monthly injection of ranibizumab from baseline through week 20 and ranibizumab as needed from week 24 through week 52.

Eligibility criteria:
inclusion criteria: * subjects will have clinically significant diabetic macular edema of ≥ 300 microns with central involvement using the heidelberg or cirrus machine * best corrected visual acuity of 20/32 to 20/320 inclusive in the study eye * adults ≥ 18 years of age with type 1 or 2 diabetes mellitus with diabetic macular edema exclusion criteria: * history of vitreoretinal surgery in the study eye * panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening * any prior laser in study eye * previous use of intraocular or periocular corticosteroids in the study eye within 6 months of screening * previous treatment with anti-angiogenic drugs in either eye within 3 months of screening * uncontrolled diabetes mellitus with hba1c levels greater than 12 * ocular disorders in the study eye, other than diabetic macular edema, that my confound interpretation of study results
leveraging videos and community health workers to address social determinants of health in immigrants

Conditions: Type 2 Diabetes

Summary: the overall goal of this study is to examine the efficacy of the video-based diabetes self-management education and support (dsmes) (hereafter video), or the video-based dsmes+community health worker (chw) intervention (hereafter video+chw), compared with a wait-list control group (hereafter control) to improve glycemic control among chinese immigrants with uncontrolled type 2 diabetes in nyc.

participants will be randomized with equal allocation to one of the 3 groups. the video group will receive 1 dsmes brief video/week for 24 weeks delivered via text message. the video+chw group will receive the same dsmes videos plus bi-weekly support calls from a chw for 24 weeks. the chw will assess participants' social determinants of health (sdoh) barriers to type 2 diabetes care and link them to available resources in the community. the control group will continue to receive their usual care and at the end of the study, they will receive dsmes videos.

Eligibility criteria:
inclusion criteria: * self-identify as a chinese immigrant; * be between 18-70 years old; * have a diagnosis of type 2 diabetes (t2d) in the medical record; * have had an appointment with a physician for routine t2d care within the past 12 months; * have a most recent hba1c of at least 8%; * be willing to receive brief videos regarding t2d management; and * possess a smartphone or, if they do not have one, be willing and able to use a study smartphone. exclusion criteria: * unable or unwilling to provide informed consent; * unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); * unwilling to accept randomization assignment; * is pregnant, plans to become pregnant in the next 6 months, or becomes pregnant during the study; or * is breastfeeding (e.g., they may have potential dietary restrictions).